Giovanni Caforio, Bristol Myers Squibb CEO (Pablo Martinez Monsivais/AP Images)

Amid JAK de­ba­cle, Bris­tol My­ers set­tles in for FDA's long re­view of po­ten­tial first TYK2 drug

Bris­tol My­ers Squibb has $4 bil­lion hopes for its late-stage TYK2 in­hibitor deu­cravac­i­tinib, but the FDA’s re­cent neg­a­tive re­view for the JAK in­hibitor class has damp­ened hopes some­what. Now, the agency will get its first good look at TYK2, and Bris­tol My­ers will have to wait and hold its breath.

The FDA has set a tar­get re­view date of Sept. 10, 2022, for deu­cravac­i­tinib, a po­ten­tial first-in-class oral in­hibitor for the TYK2 sig­nal­ing path­way in pso­ri­a­sis that would be a chal­lenger to the con­tro­ver­sial JAK in­hibitors, the drug­mak­er said Mon­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.